CN Patent

CN107426997A — 使用n‑乙酰半胱氨酸酰胺治疗视网膜色素变性

Assigned to Brighton Biotech Inc · Expires 2017-12-01 · 8y expired

What this patent protects

本发明包括用于治疗人视网膜色素变性的方法，其包括给予该人治疗有效量的N‑乙酰半胱氨酸酰胺(NACA)。根据实施方案，本发明提供用于治疗动物视网膜色素变性的方法，其包括给予该动物治疗有效量的N‑乙酰半胱氨酸酰胺(NACA)。

USPTO Abstract

本发明包括用于治疗人视网膜色素变性的方法，其包括给予该人治疗有效量的N‑乙酰半胱氨酸酰胺(NACA)。根据实施方案，本发明提供用于治疗动物视网膜色素变性的方法，其包括给予该动物治疗有效量的N‑乙酰半胱氨酸酰胺(NACA)。

Drugs covered by this patent

Patent Metadata

Patent number
CN107426997A
Jurisdiction
CN
Classification
—
Expires
2017-12-01
Drug substance claim
No
Drug product claim
No
Assignee
Brighton Biotech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.